Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines

Journal of Nanoscience and Nanotechnology

Volumn 6, Issue 9-10, 2006, Pages 3062-3069

  Serpe, Loredana ^a   Guido, Marilena ^a   Canaparo, Roberto ^a   Muntoni, Elisabetta ^a   Cavalli, Roberta ^a   Panzanelli, Patrizia ^a   Pepa, Carlo Della ^a   Bargoni, Alessandro ^a   Mauro, Alessandro ^a   Gasco, Maria Rosa ^b   Eandi, Mario ^a   Zara, Gian Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b NANOVECTOR S R L   (Italy)

Author keywords

Doxorubicin; Liposomes; Solid Lipid Nanoparticles

Indexed keywords

ADENOCARCINOMA; CYTOTOXICITY; DOXORUBICIN; LIPOSOMES; SOLID LIPID NANOPARTICLES (SLN);

CELLS; CONTROLLED DRUG DELIVERY; GROWTH KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPIDS; NANOSTRUCTURED MATERIALS; ONCOLOGY; POLYETHYLENE GLYCOLS; TOXICITY; TUMORS;

DRUG PRODUCTS;

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; DRUG CARRIER; LIPOSOME; MACROGOL DERIVATIVE; NANOMATERIAL;

ARTICLE; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; HUMAN; INTRACELLULAR FLUID; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; HUMANS; INTRACELLULAR FLUID; LIPOSOMES; NANOSTRUCTURES; NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 33750056080     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2006.423     Document Type: Conference Paper

References (31)

1. G. Barrat, Cell. Mol. Life Sci. 60, 21 (2003).
2. R. B. Weiss, Semin. Oncol. 19, 670 (1992).
3. D. J. Booser and O. N. Hortobagyi, Drugs 47, 223 (1994).
4. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, Pharmacol. Rev. 56, 185 (2004).
5. P. G. Tardi, N. L. Boman, and P. R. Cullis, J. Drug Target. 4, 129 (1996).
6. D. M. Vail, M. A. Amantea, G. T. Colbern, F. J. Martin, R. A. Hilger, and P. K. Working, Semin. Oncol. 31, 16 (2004).
7. Y. L. Tseng, J. J. Liu, and R. L. Hong, Mol. Pharmacol. 62, 864 (2002).
8. R. D. Hofheinz, S. U. Gnad-Vogt, U. Beyer, and A. Hochhaus, Anti-Cancer Drugs 16, 691 (2005).
9. S. M. Moghimi, A. C. Hunter, and J. C. Murray, Pharmacol. Rev. 53, 283 (2001).
10. K. Manjunath, J. S. Reddy, and V. Venkateswarlu, Met. Find. Exp. Clin. Pharmacol. 27, 127 (2005).
11. A. Bargoni, R. Cavalli, O. Caputo, A. Fundaro', M. R. Gasco, and G. P. Zara, Pharmaceut. Res. 15, 745 (1998).
12. G. P. Zara, A. Bargoni, R. Cavalli, A. Fundaro', D. Vighetto, and M. R. Gasco, J. Pharmaceut. Sci. 91, 1324 (2002).
13. A. Bargoni, R. Cavalli, G. P. Zara, A. Fundaro', O. Caputo, and M. R. Gasco, Pharmacol. Res. 43, 497 (2001).
14. R. Cavalli, M. R. Gasco, P. Chetoni, S. Burgalassi, and M. F. Saettone, Int. J. Pharma. 238, 241 (2002).
15. A. Fundarò, R. Cavalli, A. Bargoni, D. Vighetto, G. P. Zara, and M. R. Gasco, Pharmacol. 42, 337 (2000).
16. G. P. Zara, R. Cavalli, A. Bargoni, A. Fundarò, D. Vighetto, and M. R. Gasco, J. Drug Target. 10, 327 (2002).
17. A. Miglietta, R. Cavalli, C. Bocca, L. Gabriel, and M. R. Gasco, Int. J. Pharm. 210, 61 (2000).
18. L. Serpe, M. G. Catalano, R. Cavalli, E. Ugazio, O. Bosco, R. Canaparo, E. Muntoni, R. Frairia, M. R. Gasco, M. Eandi, and G. P. Zara, Ew. J. Pharm. Biopharm. 58, 673 (2004).
19. D. A. Brown, T. Malkin, and G. K. Maliphant, J. Chem. Soc. 1584 (1955).
20. R. Cavalli, O. Caputo, and M. R. Gasco, Int. J. Pharm. 89, 9 (1993).
21. L. M. Rose, K. F. Tillery, S. M. el Dareer, and D. L. Hill, J. Chromatog. 425, 419 (1988).
22. D. E. Koppel, J. Chem. Phys. 57, 4814 (1972).
23. R. J. Hunter, in Principles and Applications, Academic Press, London (1981).
24. C. Muller, E. Chatelut, V. Gualano, M. De Forni, F. Huguet, M. Attal, P. Canal, and G. Laurent, Cancer Chemother. Pharmacol. 379 (1993).
25. V. S. Shenoy, I. K. Vijay, and R. S. Murthy, J. Pharm. Pharmacol. 57, 411 (2005).
26. G. P. Zara, R. Cavalli, A. Fundarò, A. Bargoni, O. Caputo, and M. R. Gasco, Pharm. Res. 44, 281 (1999).
27. M. Alvarez, R. Robey, V. Sandor, K. Nishiyama, Y. Matsumoto, K. Paull, S. Bates, and T. Fojo, Mol Pharmacol. 54, 802 (1998).
28. G. Liu, Y. Akasaki, H. T. Khong, C. J. Wheeler, A. Das, K. L. Black, and J. S. Yu, Oncogene 24, 5226 (2005).
29. Y. P. Hu, N. Henry-Toulmè, and J. Robert, Eur. J. Cancer 31, 389 (1995).
30. C. Ferraro, L. Quemeneur, A. F. Prigent, C. Taverne, J. P. Revillard, and N. Bonnefoy-Berard, Cancer Res. 60, 1901 (2000).
31. L. Serpe, S. Laurora, S. Pizzimenti, E. Ugazio, R. Ponti, R. Canaparo, F. Briatore, G. Barrera, M. R. Gasco, M. G. Bernengo, M. Eandi, and G. P. Zara, Anticancer Drugs 15, 525 (2004).